PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.
Px Wire May 2023
Volume 13, Number 2
HIV Prevention Research & Development Investments 2021
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
Global Investment in HIV Cure Research & Development in 2021
A decade of progress
AVAC Partnership Strategy 2023-2026
This document lays out AVAC’s plan to transition away from traditional power structures when working with partners — from civil society advocates to scientists, policy makers, program implementers, and more. AVAC strives towards a model in which those with lived experience and field expertise have influence and equal voice in the design and delivery of plans and priorities.
CASPRiffic: March 2023 edition
See here the March 2023 edition of CASPRiffic. CASPRiffic is a monthly round-up of all that happened CASPR-related and what’s to come in the coming months.
Px Wire February 2023
Volume 13, Number 1
This issue offers data from Q4 of 2022, when South Africa became the fourth country in the world to approve injectable cabotegravir (CAB) for PrEP; the dapivirine vaginal ring (DVR) was approved in a growing number of countries; and oral PrEP use was on the rise, passing the mark of 3.8 million initiations. For the first time, the world has multiple biomedical interventions to offer choice, and it’s essential to develop the programs that bring the fruits of science to the communities facing public health threats, while continuing to invest in developing new options to meet diverse needs.
Advancing HIV Prevention Research in Pregnant and Lactating People (PLP): Think Tank Report & Action Plan
The work of the AVAC/PHASES think tank to advance HIV prevention research with pregnant and lactating people was importantly grounded in a trio of conceptual frameworks: 1. Reproductive Justice, 2. Conceptual shifts articulated in the Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Ethics Guidance and 3. WHO/ IMPAACT framework for accelerated inclusion of pregnant women in pre-licensure clinical trials.
Prevent, Prepare, and Respond: An analysis of global health architecture for pandemic preparedness
2023 will be a pivotal year for global health and the structures that are set up to address it. Decisions being made at the highest levels of government will determine how prepared we are for future pandemics and will reshape how we respond to ongoing ones. AVAC is keen to articulate policy positions on these structural shifts and global policy changes that will determine – among other things – the future of the HIV response.
Picking Up the Pace
PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more.
Biomedical HIV Prevention Research in 2022 and Beyond
This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.